NuGEN launches Ovation whole blood solution and RNA amplification system
7 December 2006 SAN CARLOS, Calif.--(BUSINESS WIRE)--NuGEN,
Technologies, Inc., has announced the release of a modular amplification
system for RNA from any source, and a modular solution for amplification of
RNA isolated from whole blood, allowing analysis on the Affymetrix GeneChip
without the need for globin reduction.
These products follow closely on NuGEN’s September launch of WT-Ovation
Pico RNA Amplification System and the FL-Ovation™ cDNA Biotin Module V2,
highlighting the rapidly growing market acceptance of the NuGEN Ovation
System family of products as the gold standard for amplification and target
preparation for differential expression analysis of small and difficult
samples and high throughput applications. The new Ovation RNA
Amplification System V2 replaces the Ovation RNA Biotin Amplification and
Labeling System when used in conjunction with FL-Ovation cDNA Biotin Module
V2. The modular system offers flexibility, is especially well suited for
automation, and yields micrograms of amplified cDNA in under 4 hours for
qPCR and for fragmentation and labeling for microarray analysis. NuGEN is
also launching the Ovation WB Reagent for the Ovation Whole Blood Solution.
This product is part of a solution that includes two other NuGEN products,
enabling gene expression analysis of as little as 20 nanograms of whole
blood RNA on GeneChip arrays in just one day, without the need for Globin
reduction,. “The Whole Blood Solution enables amplification of small amounts
of RNA from whole blood rapidly and cleanly,” said Garry Miyada, vice
president of development at NuGEN. “The cDNA generated by this process is
obtained with fewer sample manipulations than alternative approaches, and
affords excellent results on GeneChip microarrays.”
“NuGEN continues to expand accessibility to increasing numbers of sample
types for scientists carrying out differential gene expression research,”
said Sue Pandey, vice president of commercial operations for NuGEN. “The
launch of these products demonstrates our commitment to meet the challenges
facing today’s discovery and clinical research laboratories in high
throughput gene expression analysis.” To top
|
|